Undifferentiated Pleomorphic Sarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Undifferentiated Pleomorphic Sarcoma (UPS) is a rare and aggressive type of sarcoma that can originate in any body part, including soft tissue and bone. The tumor is most commonly diagnosed in individuals between the ages of 60 and 70, with the most common sites of involvement being the lower extremities, particularly the thigh, upper arms, retroperitoneum, viscera, head, and neck (in childhood cases). High local recurrence rates and significant metastasis typically characterize it. Symptoms of UPS may include swelling, mass, pain, pathological fractures, and systemic features such as anorexia, malaise, fever, and weight loss. Treatment for UPS typically involves wide surgical excision; sometimes, amputation may be necessary to remove the entire lesion. Adjuvant radiotherapy is often given for high-grade, large, deep-seated tumors, in limb-sparing surgeries, and when negative margins are not obtained. Primary radiation therapy may be an option for inoperable sarcomas, but chemotherapy regimens containing doxorubicin are typically preferred in the first-line setting for locally irresectable and metastatic lesions. Chemotherapy with ifosfamide, trabectedin, dacarbazine, and pazopanib has demonstrated efficacy in UPS and is available in most European Union countries. The overall 5-year survival rate for UPS ranges from 48% for patients with head and neck tumors to 77% for patients with tumors arising on the trunk and extremities. The prognosis for the childhood variant of UPS appears to be better than for adult cases.

·       The SEER program reports that among 26,758 cases, 17.1% were UPS, making it the second most frequent STS after leiomyosarcoma, regardless of the primary tumor location. Males have a significantly higher incidence rate than females.

Thelansis’s “Undifferentiated Pleomorphic Sarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Undifferentiated Pleomorphic Sarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Undifferentiated Pleomorphic Sarcoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Undifferentiated Pleomorphic Sarcoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Undifferentiated Pleomorphic Sarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more